Vor Biopharma (VOR) Enterprise Value (2021 - 2026)

Vor Biopharma (VOR) has reported Enterprise Value for 7 consecutive years, with -$491.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 718.73% year-over-year to -$491.5 million; the TTM figure through Mar 2026 stood at -$491.5 million (down 718.73% YoY), while the FY2025 annual figure was -$455.2 million, down 395.19% from the prior year.
• Enterprise Value retreated to -$491.5 million in Q1 2026 per VOR's latest filing, from -$455.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$60.0 million in Q1 2025 and bottomed at -$491.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$183.5 million across 5 years, with a median of -$160.1 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 60.77% — and 2026, when it tumbled 718.73%.
• Vor Biopharma's Enterprise Value stood at -$230.2 million in 2022, then surged by 40.42% to -$137.2 million in 2023, then surged by 32.99% to -$91.9 million in 2024, then sank by 395.19% to -$455.2 million in 2025, then dropped by 7.98% to -$491.5 million in 2026.
• Business Quant data shows VOR's Enterprise Value at -$491.5 million in Q1 2026, -$455.2 million in Q4 2025, and -$170.5 million in Q3 2025.